Evidence map›Paper›PMID 34211556›Full record

ReviewStem cells international2021

Characteristics and Developments in Mesenchymal Stem Cell Therapy for COVID-19: An Update.

Lu Sang, Xiaoqin Guo, Jie Shi, Shike Hou, Haojun Fan, Qi Lv

Open access · goldAbstract readReview
In one paragraph

Review in Stem cells international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Immunomodulation and Regenerative Capacity of MSCs for Long-COVID.International journal of molecular sciences · 2021
    Review
  4. The Phosphonate Derivative of CInternational journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lu SangInstitute of Disaster Medicine, Tianjin University, Tianjin, China.ORCID https://orcid.org/0000-0002-1703-5344
Xiaoqin GuoInstitute of Disaster Medicine, Tianjin University, Tianjin, China.ORCID https://orcid.org/0000-0003-1647-4385
Jie ShiInstitute of Disaster Medicine, Tianjin University, Tianjin, China.ORCID https://orcid.org/0000-0001-8921-9559
Shike HouInstitute of Disaster Medicine, Tianjin University, Tianjin, China.ORCID https://orcid.org/0000-0001-6097-0867
Haojun FanInstitute of Disaster Medicine, Tianjin University, Tianjin, China.ORCID https://orcid.org/0000-0003-1111-0232
Qi LvInstitute of Disaster Medicine, Tianjin University, Tianjin, China.ORCID https://orcid.org/0000-0001-9076-7042
Tianjin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) has so far resulted in over a hundred million people being infected. COVID-19 poses a threat to human health around the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been confirmed as the pathogenic virus of COVID-19. SARS-CoV-2 belongs to the

Identifiers

PMID34211556
PMCPMC8205583
OpenAlexW3168141117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.